(Q38155126)

29 August 2017

title

Tocilizumab: a review of its use in the treatment of juvenile idiopathic arthritis (English)

1 reference

juvenile rheumatoid arthritis

29 August 2017

main subject

1 reference

1 reference

James E Frampton

1

1 reference

29 August 2017

publication date

1 December 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

15

1 reference

29 August 2017

issue

6

1 reference

29 August 2017

page(s)

515-531

1 reference

Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0053-1

Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0053-1

Systemic arthritis in children: a review of clinical presentation and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0053-1

Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0053-1

Current treatment of juvenile rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0053-1

Medical treatment of juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0053-1

Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0053-1

The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0053-1

Targeting interleukin-6 in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0053-1

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0053-1

Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0053-1

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0053-1

Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0053-1

Tocilizumab: a review of its use in the management of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0053-1

Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0053-1

Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0053-1

Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0053-1

IL-6: from its discovery to clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0053-1

IL-6/IL-6 receptor system and its role in physiological and pathological conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0053-1

IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0053-1

The IL-6/sIL-6R complex as a novel target for therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0053-1

Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0053-1

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0053-1

Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0053-1

Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0053-1

Tocilizumab for the treatment of juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0053-1

Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0053-1

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0053-1

Long-term treatment of systemic juvenile idiopathic arthritis with tocilizumab: results of an open-label extension study in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0053-1

Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0053-1

Tocilizumab-effects on growth impairment in systemic juvenile idiopathic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0053-1

Infectious risks associated with biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0053-1

Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0053-1

Pharmacokinetics and pharmacodynamics of tocilizumab after subcutaneous administration in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0053-1

A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0053-1

Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis

21 January 2018

1 reference

12 December 2020

Juvenile idiopathic arthritis

1 reference

12 December 2020

Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial

1 reference

12 December 2020

Guidance on using tocilizumab for juvenile idiopathic arthritis.

1 reference

12 December 2020

Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group

1 reference

12 December 2020

Tocilizumab for systemic juvenile idiopathic arthritis

1 reference

12 December 2020

Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6

1 reference

12 December 2020

Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis?

1 reference

12 December 2020

Tocilizumab in the treatment of systemic juvenile idiopathic arthritis

1 reference

12 December 2020

International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001

1 reference

12 December 2020

Outcome in adults with juvenile idiopathic arthritis: a quality of life study

1 reference

12 December 2020

Radiographic improvement of damaged large joints in children with systemic juvenile idiopathic arthritis following tocilizumab treatment

1 reference

12 December 2020

Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab

1 reference

12 December 2020

10.1007/S40272-013-0053-1

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1011037257

0 references

1 reference